BB Biotech AG (BBZA.DE)
EUR 39.05
(0.77%)
EUR 39.05
(0.77%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 218.27 Million | -357.81 Million | -94.78 Million | 262.44 Million | 215.02 Million | -471.34 Million |
| Net Income | -206.6 Million | -357.81 Million | -404.8 Million | 691.17 Million | 677.43 Million | -471.34 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | 424.88 Million | 357.81 Million | 310.02 Million | -428.72 Million | -462.41 Million | 471.34 Million |
| Investing Cash Flow | - | 588.94 Million | - | - | - | 579.13 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -220.21 Million | -233.27 Million | 91.76 Million | -284.48 Million | -205.21 Million | -93.9 Million |
| Debt repayment | -58.1 Million | -8 Million | -292 Million | -87 Million | -35 Million | - |
| Dividends payments | -156.31 Million | -212.24 Million | -199.44 Million | -188.36 Million | -168.97 Million | -182.82 Million |
| Common Stock Repurchased | - | -27.3 Million | -9.45 Million | -8.26 Million | - | - |
| Common Stock Issuance | - | - | 9.65 Million | 20 Thousand | - | - |
| Other Financing Activities | -5.8 Million | 6.27 Million | 291.01 Million | -883 Thousand | -36.24 Million | 88.91 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 1.94 Million | 2.83 Million | 6.81 Million | 30.7 Million | 22.07 Million | 10.73 Million |
| Cash at end of period | 501 Thousand | 1.94 Million | 2.83 Million | 6.81 Million | 30.7 Million | 22.07 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | 490 Thousand | 1.25 Million | -962 Thousand | -1.85 Million | -1.17 Million | -2.54 Million |
| Net cash flow / Change in cash | -1.44 Million | -887 Thousand | -3.98 Million | -23.89 Million | 8.63 Million | 11.34 Million |
| Free Cash Flow | 218.27 Million | -357.81 Million | -94.78 Million | 262.44 Million | 215.02 Million | -471.34 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -87.08 Million | 260.49 Million | -206.6 Million | 109.11 Million | -48.39 Million | -13.47 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | 113.85 Million | -189.24 Million | 424.88 Million | -110.04 Million | 55.78 Million | 22.2 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -26.87 Million | -71.32 Million | -220.21 Million | 1.21 Million | -8.06 Million | -8.44 Million |
| Debt repayment | -25.3 Million | -39.8 Million | -58.1 Million | -2.8 Million | -6.4 Million | -7 Million |
| Dividends payments | - | -109.69 Million | -156.31 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -26.87 Million | 38.36 Million | -5.8 Million | 4.01 Million | -1.66 Million | -1.44 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 405 Thousand | 501 Thousand | 1.94 Million | 322 Thousand | 900 Thousand | 759 Thousand |
| Cash at end of period | 317 Thousand | 405 Thousand | 501 Thousand | 501 Thousand | 322 Thousand | 900 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | 6000.00 | -16 Thousand | 490 Thousand | -110 Thousand | 100 Thousand | -144 Thousand |
| Net cash flow / Change in cash | -88 Thousand | -96 Thousand | -1.44 Million | 179 Thousand | -578 Thousand | 141 Thousand |
| Free Cash Flow | 26.77 Million | 71.24 Million | 218.27 Million | -928 Thousand | 7.39 Million | 8.72 Million |
ALGEV
2871
ENR
002232
1723
COEP